( aluateTraficet-EN's safety and tolerab...)ChemoCentryx Presents Positive Phase 2 Clinical Data for,Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007,Conference,Health

aluate Traficet-EN's safety and tolerability among patients with moderate-to-severe Crohn's disease. Traficet-EN was well-tolerated by patients participating in the Phase 2 study and the incidence of adverse events reported was generally similar in both the placebo and Traficet-EN groups.

ChemoCentryx is currently evaluating Traficet-EN in a large multi-national clinical trial. PROTECT-1 or the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial is a randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Traficet-EN in patients with moderate-to-severe Crohn's disease. The study includes a 12-week Induction Period to evaluate the drug's ability to induce response/remission and a 36-week Maintenance Period to evaluate the drug's ability to maintain a treatment response.

About Traficet-EN

Traficet-EN, a small molecule, orally-available drug, is intended to control the inappropriate immune system response underlying inflammatory bowel disease (IBD) by blocking the activity of the CCR9 chemokine receptor. In adults, CCR9 is a highly specific receptor expressed by T cells that migrate selectively to the digestive tract. The trafficking of T cells to the small and large intestine causes persistent inflammation that may result in Crohn's disease or ulcerative colitis -- the two principal forms of IBD. In preclinical studies, the compound worked both therapeutically and prophylactically in Crohn's disease. ChemoCentryx has completed four Phase I trials and one four-week Phase 2 trial of Traficet-EN demonstrating that the product candidate is well-tolerated and appropriate for once- or twice-daily oral dosing.

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups or periods characterized by intense symptoms, in
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
3. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
4. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
7. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
8. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
9. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
10. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
11. BioCryst Presents Phase I Peramivir Data at the Options for the Control of Influenza Conference